Omega-3 fish oil shows promise against non-obese type 2 diabetes

A Brazilian study found that fish oil supplements reduced insulin resistance and inflammation in rats modeling non-obese type 2 diabetes. The research highlights a potential role for omega-3 fatty acids in cases where obesity is not a factor.

Researchers at institutions including the Butantan Institute gave Goto-Kakizaki rats fish oil three times a week for eight weeks. The dose equaled 2 grams per kilogram of body weight and contained specific amounts of EPA and DHA. Treated animals showed lower insulin resistance, improved blood sugar control, reduced inflammatory markers, and better cholesterol and triglyceride levels.

Labaran da ke da alaƙa

Pediatrician assessing overweight children in clinic, highlighting study-recommended early treatment to prevent adult risks like diabetes and hypertension.
Hoton da AI ya samar

Study recommends treatment for all children with obesity

An Ruwaito ta hanyar AI Hoton da AI ya samar

A new Karolinska Institutet study finds that children with moderate obesity face higher risks of type 2 diabetes, high blood pressure, and lipid disorders in adulthood, even without apparent risk markers. Researchers urge treatment for all such children.

New research from Yale shows that oleic acid, the main fat in olive oil, accelerated tumor growth in mice prone to pancreatic cancer, while omega-3 fats from fish oil cut disease development by half.

An Ruwaito ta hanyar AI

A major Spanish clinical trial has shown that a modified Mediterranean diet, combined with calorie restriction, physical activity and professional support, reduced the risk of type 2 diabetes by 31 percent over six years. The findings come from the PREDIMED-Plus study involving nearly 5,000 adults with overweight or obesity.

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

An Ruwaito ta hanyar AI

A specially formulated tomato-soy juice lowered several markers of inflammation in adults with obesity after four weeks of daily consumption. The beverage, rich in lycopene and soy isoflavones, outperformed a control tomato juice in a small clinical trial led by researchers at The Ohio State University.

Wannan shafin yana amfani da cookies

Muna amfani da cookies don nazari don inganta shafin mu. Karanta manufar sirri mu don ƙarin bayani.
Ƙi